Title
Anti-C1q antibodies in systemic lupus erythematosus
Date Issued
01 January 2015
Access level
open access
Resource Type
journal article
Author(s)
Orbai A.M.
Truedsson L.
Sturfelt G.
Nived O.
Fang H.
Gordon C.
Merrill J.T.
Fortin P.R.
Bruce I.N.
Isenberg D.A.
Wallace D.J.
Ramsey-Goldman R.
Bae S.C.
Hanly J.G.
Sanchez-Guerrero J.
Clarke A.E.
Aranow C.B.
Manzi S.
Urowitz M.B.
Gladman D.D.
Kalunian K.C.
Costner M.I.
Werth V.P.
Zoma A.
Bernatsky S.
Ruiz-Irastorza G.
Khamashta M.A.
Jacobsen S.
Buyon J.P.
Maddison P.
Dooley M.A.
Van Vollenhoven R.F.
Ginzler E.
Stoll T.
Peschken C.
Jorizzo J.L.
Callen J.P.
Lim S.S.
Fessler B.J.
Inanc M.
Kamen D.L.
Rahman A.
Steinsson K.
Franks A.G.
Sigler L.
Hameed S.
Pham N.
Brey R.
Weisman M.H.
McGwin G.
Magder L.S.
Petri M.
University of Alabama at Birmingham
Publisher(s)
SAGE Publications Ltd
Abstract
Objective: Anti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.
Start page
42
End page
49
Volume
24
Issue
1
Language
English
OCDE Knowledge area
Reumatología
Subjects
Scopus EID
2-s2.0-84918547572
PubMed ID
Source
Lupus
ISSN of the container
09612033
Sponsor(s)
Dr Gunnar Sturfelt and Dr Lennart Truedsson are supported by grants from the Greta and Johan Kock's Foundation, King Gustaf V's 80th Birthday Foundation and the Swedish Rheumatism Association.
This work was supported in the form of grants or industrial support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and Lupus Foundation of America, and an unrestricted research grant from Human Genome Sciences.
Professor I. Bruce is a National Institute for Health Research (NIHR) Senior Investigator and is supported by Arthritis Research UK, The Manchester Academic Health Science Centre, the NIHR Manchester Musculoskeletal Biomedical Research Unit, The NIHR Manchester Wellcome Trust Clinical Research Facility and the Manchester Biomedical Research Centre. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health.
Dr Paul R. Fortin is supported by a Canada Research Chair on Systemic Autoimmune Rheumatic Diseases.
Dr David A. Isenberg and Dr Anisur Rahman are supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.
Dr Caroline Gordon is supported by Lupus UK.
Dr Ana‐Maria Orbai is supported by National Institutes of Health (NIH) grant T32 AR048522.
Dr Sang-Cheol Bae is supported by the Korea Healthcare Technology R & D Project, Ministry for Health and Welfare, Republic of Korea (A120404).
Sources of information:
Directorio de Producción Científica
Scopus